Wei Shanshan, Wang Zheng, Li Shiyong, Ren Hanwen, Wang Yuanli, Xiao Haolin, Zhao Feijun, Zhu Jianming, Chen Zhencheng
School of Electronic Engineering and Automation, Guilin University of Electronic Technology, Guilin, 541004, China.
Institute of Optoelectronic Materials and Devices, College of Optical and Electronic Technology, China Jiliang University, Hangzhou, 310018, China.
Talanta. 2025 Jan 1;282:126961. doi: 10.1016/j.talanta.2024.126961. Epub 2024 Sep 28.
Developing immunosensing platforms capable of simultaneously detecting multiple cancer markers is crucial for clinical diagnosis and biomedical research. Here, we introduce a novel dual-mode electrochemical biosensing assay platform capable of detecting two gastric cancer biomarkers: pepsinogen I (PG I) and pepsinogen II (PG II). Methylene blue (MB) and Prussian blue (PB) were used as dual signal sources to label PG I and PG II, respectively. The platform integrates an ARM STM32F411 microcontroller and an AD5941 analog front-end, which not only facilitates cyclic voltammetry (CV) and differential pulse voltammetry (DPV) with efficacy comparable to commercial electrochemical workstations but also offers data collection and synchronous analysis capabilities, allowing simultaneous output of PG I and PGR (PG I/PG II) values. Equipped with an interactive screen for operational control and result display, the immunosensing platform provides linear detection ranges for PG I (5 pg/mL-100 ng/mL) and PG II (50 pg/mL-200 ng/mL), enabling rapid detection within 5 min. It demonstrates excellent sensitivity and selectivity when comparing serum samples from healthy individuals and gastric cancer patients. The dual-marker detection platform significantly enhances early diagnosis and screening of gastric cancer, offering substantial improvements over single-marker assays. Furthermore, this platform shows potential for detecting multiple biomarkers in various diseases, highlighting its utility for biomedical applications.
开发能够同时检测多种癌症标志物的免疫传感平台对于临床诊断和生物医学研究至关重要。在此，我们介绍一种新型的双模式电化学生物传感检测平台，它能够检测两种胃癌生物标志物：胃蛋白酶原I（PG I）和胃蛋白酶原II（PG II）。亚甲蓝（MB）和普鲁士蓝（PB）分别用作双信号源来标记PG I和PG II。该平台集成了一个ARM STM32F411微控制器和一个AD5941模拟前端，不仅能高效地进行循环伏安法（CV）和差分脉冲伏安法（DPV），其效果与商用电化学工作站相当，还具备数据采集和同步分析能力，可同时输出PG I和PGR（PG I/PG II）值。该免疫传感平台配备了用于操作控制和结果显示的交互式屏幕，为PG I（5 pg/mL - 100 ng/mL）和PG II（50 pg/mL - 200 ng/mL）提供线性检测范围，能够在5分钟内实现快速检测。在比较健康个体和胃癌患者的血清样本时，它表现出出色的灵敏度和选择性。这种双标志物检测平台显著提高了胃癌的早期诊断和筛查能力，比单标志物检测有了实质性的改进。此外，该平台在检测多种疾病的多种生物标志物方面显示出潜力，突出了其在生物医学应用中的实用性。
